A recent study found that combining nivolumab with chemotherapy improved progression-free survival in patients with advanced Hodgkin lymphoma compared to standard care. The study, which included both children and adults, showed higher rates of PFS and fewer adverse events among patients receiving nivolumab. The combination treatment was found to be more effective and less toxic than the standard regimen. Experts believe that nivolumab plus chemotherapy may become the preferred treatment option for all stages of Hodgkin lymphoma. Further research is needed to evaluate long-term outcomes and potential predictors of response to this regimen.
Source link
Nivolumab regimen halves risk for progression, death in Hodgkin lymphoma
